



29th January, 2019

To, Department of Corporate Services BSE Ltd. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. Ref.: Scrip Code No. : 540701	To, The Manager, Listing Department, National Stock Exchange of India Ltd. “Exchange Plaza”, C-1, Block G, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. Ref. : (i) Symbol – DCAL (ii) Series – EQ
--	--

SUB.: DISCLOSURE PURSUANT TO REGULATION 30 OF SEBI (LODR) REGULATIONS, 2015: COMPANY'S BAVLA UNIT RECEIVED ESTABLISHMENT INSPECTION REPORT (EIR) FROM US FDA

Dear Sir,

With reference to the captioned subject, we would like to inform that the Company's Bavla facility was successfully inspected by the US FDA in October 2018, which was intimated to the stock exchange on 27th October 2018. We are pleased to share that we have received the Establishment Inspection Report (EIR) from the US FDA for this facility yesterday.


Thus, the Company's facilities in Bavla and Naroda in India, multiple facilities in Switzerland and the Netherlands continue to be approved by the US FDA.

Kindly take this on your record.

Thanking You,

Yours faithfully,
For, Dishman Carbogen Amcis Limited


Shrima Dave
Company Secretary



Dishman Carbogen Amcis Limited
(Formerly Carbogen Amcis (I) Ltd)

DISHMAN CORPORATE HOUSE
Iscon-Bopal Road, Ambli, Ahmedabad-380 058. (India)
Phone : +91 (0) 2717 420100 / 420124
E-mail : dcal@dishmangroup.com
Website : www.dishmangroup.com

Regd. Off.: Bhadra-Raj Chambers, Swastik Cross Road,
Navrangpura, Ahmedabad-380 009. (India)
Phone : +91 (0) 79 26443053 / 26445807 / 26560089
Fax : +91 (0) 79 26420198

Government Recognised Export House
CIN No. : L74900GJ2007PLC051338